checkAd

     152  0 Kommentare Aerie Pharmaceuticals Announces Successful Interim 90-Day Topline Data From Its Six-Month Mercury 3 Clinical Trial in Europe - Seite 4


    Business Wire (engl.)
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 4 von 4

    Verfasst von Business Wire (engl.)
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Aerie Pharmaceuticals Announces Successful Interim 90-Day Topline Data From Its Six-Month Mercury 3 Clinical Trial in Europe - Seite 4 Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases …